CTDSPL2 and non-small cell lung carcinoma: To investigate the potential of CTDSPL2 to promote NSCLC cell proliferation via JAK1/PI3K/AKT signaling, we administered ruxolitinib (20 μM) or LY294002 (20 μM), a PI3K inhibitor, to A549 cells stably expressing CTDSPL2.